Telix Pharmaceuticals Lim... (TLX)
| Bid | 9.6 |
| Market Cap | 3.48B |
| Revenue (ttm) | 1.19B |
| Net Income (ttm) | 34.76M |
| EPS (ttm) | 0.02 |
| PE Ratio (ttm) | 514 |
| Forward PE | 31.94 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 10.3 |
| Volume | 131,185 |
| Avg. Volume (20D) | 166,080 |
| Open | 10.29 |
| Previous Close | 10.22 |
| Day's Range | 10.21 - 10.31 |
| 52-Week Range | 8.93 - 30.36 |
| Beta | 2.27 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for TLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not InsurmountableDespite recent FDA rejections and a ~50% share price drop, I remain bullish on TLX, viewing setbacks as surmountable. Strong revenue performance and cash flow stability provide TLX with ample runway t...
1 month ago · seekingalpha.com
Telix Pharmaceuticals Limited (TLX) Q2 2025 Earnings Call TranscriptTelix Pharmaceuticals Limited (NASDAQ:TLX ) Q2 2025 Earnings Conference Call August 20, 2025 7:30 PM ET Company Participants Christian P. Behrenbruch - Co-Founder, MD, Group CEO & Executive Director D...
1 month ago · seekingalpha.com
Telix Pharmaceuticals Limited (TLPPF) H1 2025 Earnings Call TranscriptTelix Pharmaceuticals Limited (OTCPK:TLPPF) H1 2025 Earnings Conference Call August 20, 2025 7:30 PM ET Company Participants Christian P. Behrenbruch - Co-Founder, MD, Group CEO & Executive Director D...
